Cargando…

Rituximab 500 mg 6-monthly infusions is an option in maintenance therapy of ANCA-associated vasculitis

Detalles Bibliográficos
Autores principales:	Goel, Ruchika, Morgan, Matthew, Chanouzas, Dimitrios, Caplan, Joshua, Logan, Sarah, Harper, Lorraine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Letter to the Editor (Other)
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8496757/ https://www.ncbi.nlm.nih.gov/pubmed/34632259 http://dx.doi.org/10.1093/rap/rkab039

Ejemplares similares

Valaciclovir to prevent Cytomegalovirus mediated adverse modulation of the immune system in ANCA-associated vasculitis (CANVAS): study protocol for a randomised controlled trial
por: Chanouzas, Dimitrios, et al.
Publicado: (2016)

A Case of Rituximab Use as an Induction and Maintenance of Remission in ANCA-Associated Vasculitis
por: Awad, Neveen, et al.
Publicado: (2016)

Rituximab Induction and Maintenance in ANCA-Associated Vasculitis: State of the Art and Future Perspectives
por: Treppo, Elena, et al.
Publicado: (2021)

The host cellular immune response to cytomegalovirus targets the endothelium and is associated with increased arterial stiffness in ANCA-associated vasculitis
por: Chanouzas, Dimitrios, et al.
Publicado: (2018)

Long-term maintenance rituximab for ANCA-associated vasculitis: relapse and infection prediction models
por: McClure, Mark E, et al.
Publicado: (2020)

Cytomegalovirus infection is a risk factor for venous thromboembolism in ANCA-associated vasculitis
por: King, C., et al.
Publicado: (2022)

Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis
por: Smith, Rona M, et al.
Publicado: (2020)

Avoidance of Harm From Treatment for ANCA-Associated Vasculitis
por: King, Catherine, et al.
Publicado: (2017)

Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial
por: Smith, Rona M, et al.
Publicado: (2023)

PR3-ANCAs predict relapses in ANCA-associated vasculitis patients after rituximab
por: van Dam, Laura S, et al.
Publicado: (2020)

PReS-FINAL-2311: Rituximab in paediatric ANCA-associated vasculitis
por: Mestrallet, G, et al.
Publicado: (2013)

Combination Therapy With Rituximab and Cyclophosphamide for Remission Induction in ANCA Vasculitis
por: Cortazar, Frank B., et al.
Publicado: (2017)

The Efficacy and Safety of Rituximab in ANCA-Associated Vasculitis: A Systematic Review
por: Habibi, Mohammad Amin, et al.
Publicado: (2022)

Rituximab-associated hypogammaglobulinemia in ANCA-associated vasculitis: Incidence and time course
por: Tariq, Anam, et al.
Publicado: (2022)

Intravenous pulse methylprednisolone for induction of remission in severe ANCA associated Vasculitis: a multi-center retrospective cohort study
por: Chanouzas, Dimitrios, et al.
Publicado: (2019)

Long- term outcome of paediatric patients with ANCA vasculitis
por: Arulkumaran, Nishkantha, et al.
Publicado: (2011)

Membranous Nephropathy with Proteinase 3-ANCA-associated Vasculitis Successfully Treated with Rituximab
por: Yoshida, Shun, et al.
Publicado: (2020)

COVID-19 and ANCA-associated vasculitis: recommendations for vaccine preparedness and the use of rituximab
por: Bruchfeld, Annette, et al.
Publicado: (2021)

Favorable efficacy of rituximab in ANCA-associated vasculitis patients with excessive B cell differentiation
por: Miyazaki, Yusuke, et al.
Publicado: (2020)

ANCA associated vasculitis
por: Hunter, Robert W, et al.
Publicado: (2020)

Induction treatment of previously undiagnosed ANCA-associated vasculitis in a renal transplant patient with Rituximab
por: Graham-Brown, M. P. M., et al.
Publicado: (2016)

Rituximab induction therapy for de novo ANCA associated vasculitis in pregnancy: a case report
por: Harris, Claire, et al.
Publicado: (2018)

Rapid Infusion Rituximab for Maintenance Therapy: Is It Feasible?
por: Patel, Jolly, et al.
Publicado: (2013)

Early post-transplant recurrence of ANCA vasculitis while on belatacept maintenance immunosuppression
por: Agrawal, Amogh, et al.
Publicado: (2023)

The “4 plus 2” rituximab protocol makes maintenance treatment unneeded in patients with refractory ANCA-associated vasculitis: A 10 years observation study
por: Roccatello, Dario, et al.
Publicado: (2017)

Confirmation of the genetic association of CTLA4 and PTPN22 with ANCA-associated vasculitis
por: Carr, Edward J, et al.
Publicado: (2009)

Addressing the transition to a chronic condition: exploring independent adoption of self-management by patients with ANCA-associated vasculitis
por: Litchfield, Ian, et al.
Publicado: (2021)

The immunopathology of ANCA-associated vasculitis
por: McKinney, Eoin F., et al.
Publicado: (2014)

Immunopathogenesis of ANCA-Associated Vasculitis
por: Kronbichler, Andreas, et al.
Publicado: (2020)

ANCA-associated vasculitis of the appendix
por: Leaver, Phillip J, et al.
Publicado: (2019)

Comorbidities in ANCA-associated vasculitis
por: Kronbichler, Andreas, et al.
Publicado: (2020)

ANCA-Associated Vasculitis: An Update
por: Almaani, Salem, et al.
Publicado: (2021)

Daratumumab for the treatment of refractory ANCA-associated vasculitis
por: Ostendorf, Lennard, et al.
Publicado: (2023)

A Personalized Rituximab Retreatment Approach Based on Clinical and B-Cell Biomarkers in ANCA-Associated Vasculitis
por: Arnold, Jack, et al.
Publicado: (2022)

ANCA‐associated vasculitis with scleritis, corneal melt, and perforation rescued by rituximab: Case report and literature review
por: Matsuo, Toshihiko, et al.
Publicado: (2023)

Personalized Medicine in ANCA-Associated Vasculitis ANCA Specificity as the Guide?
por: Wallace, Zachary S., et al.
Publicado: (2019)

Methotrexate versus cyclophosphamide for remission maintenance in ANCA-associated vasculitis: A randomised trial
por: Maritati, Federica, et al.
Publicado: (2017)

Subclinical Reactivation of Cytomegalovirus Drives CD4(+)CD28(null) T-Cell Expansion and Impaired Immune Response to Pneumococcal Vaccination in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
por: Chanouzas, Dimitrios, et al.
Publicado: (2019)

Case report: de novo ANCA-associated vasculitis after kidney transplantation treated with rituximab and plasma exchange
por: Sagmeister, Michael S., et al.
Publicado: (2018)

Rituximab in relapsing and de novo MPO ANCA-associated vasculitis with severe renal involvement: a case series
por: Caroti, L., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_cmtgi9mi1nb1r74qct9jjvj8kb